Journal: Journal of Family & Reproductive Health

Article Title: Effect of Lysophosphatidic Acid on the Vascular Endothelial Growth Factor Expression in Autotransplanted Mouse Ovaries Encapsulated in Sodium Alginate

doi: 10.18502/jfrh.v15i2.6449

Figure Lengend Snippet: The sequences of the designed primers

Article Snippet: The cells were permeable by putting the sections in triton X100 (0.3 % for 30 min), washed in PBS and blocked with goat serum (30 min) then, they were incubated with the primary anti-VEGF polyclonal antibody (1:100, Elabscience Biotechnology Co, Wuhan, China) overnight.

Techniques: Sequencing

Journal: Journal of Family & Reproductive Health

Article Title: Effect of Lysophosphatidic Acid on the Vascular Endothelial Growth Factor Expression in Autotransplanted Mouse Ovaries Encapsulated in Sodium Alginate

doi: 10.18502/jfrh.v15i2.6449

Figure Lengend Snippet: The fluorescent microscopy observations of transplanted mouse ovarian tissue sections immunostained for VEGF antibody (first row) and phase contrast of the same groups in second row. A and a: Intact control group; B and b: LPA+/LPA-; C and c: LPA-/LPA-. Green color shows the positive cell reaction (white arrow) for VEGF antibody (Bar=50μm). The comparison of the relative expression ratio of Vegf gene to β- actin in transplanted mouse ovaries and intact control group are shown in parts D.

Article Snippet: The cells were permeable by putting the sections in triton X100 (0.3 % for 30 min), washed in PBS and blocked with goat serum (30 min) then, they were incubated with the primary anti-VEGF polyclonal antibody (1:100, Elabscience Biotechnology Co, Wuhan, China) overnight.

Techniques: Microscopy, Control, Comparison, Expressing

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Thioredoxin-Interacting Protein Mediates NLRP3 Inflammasome Activation Involved in the Susceptibility to Ischemic Acute Kidney Injury in Diabetes

doi: 10.1155/2016/2386068

Figure Lengend Snippet: STZ-induced diabetes induces TXNIP expression and NLRP3 inflammasome activation following I/R 48. TXNIP expression was examined by IHC (a), representative blots (b), and quantitative analysis of Western blots for TXNIP (c), NLRP3 (d) and pro-caspase-1 and cleaved caspase-1 (e-f), and release of IL-1 β and IL-18 by ELISA (g-h). The data in (c–h) are means ± SE ( n = 5). ★ P < 0.05 versus NS group; # P < 0.05 versus DS group; ▲ P < 0.05 versus NI/R group; & P < 0.05 versus DI/R group. NS and DS: nondiabetic and STZ-induced diabetic rats were subjected to sham operation. NI/R and DI/R: nondiabetic and STZ-induced diabetic rats were subjected to 25 min ischemia followed by 48 h reperfusion. DI/R-RES: STZ-induced diabetic rats that underwent I/R were treated with RES (10 mg/kg, ip daily) for 7 consecutive days before renal ischemia-reperfusion.

Article Snippet: IL-1 β and IL-18 levels in kidney were assessed using a rat ELISA kit (Elabscience Biotechnology Co., Ltd., Wuhan, China) according to the manufacturer's instructions.

Techniques: Expressing, Activation Assay, Western Blot, Enzyme-linked Immunosorbent Assay

Journal: Experimental and therapeutic medicine

Article Title: Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis.

doi: 10.3892/etm.2017.4854

Figure Lengend Snippet: Figure 1. Serum and urine HMGB1 levels upon diagnosis of sepsis. (A) Serum and (B) urine levels of HMGB1 were measured by ELISA in the different patient groups prior to the initiation of treatment. Data are presented as the mean ± standard deviation. #P<0.05 vs. Control. HMGB1, high mobility group box protein 1; CRRT, continuous renal replacement treatment; HP, hemoperfusion.

Article Snippet: Serum and urine HMGB1 levels were measured using a Human HMGB1 ELISA kit (E-EL-H1554c, Elabscience Biotechnology Co., Ltd., Wuhan, China) according to the manufacturer's protocol.

Techniques: Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Standard Deviation, Control

Journal: Experimental and therapeutic medicine

Article Title: Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis.

doi: 10.3892/etm.2017.4854

Figure Lengend Snippet: Figure 2. Changes in serum and urine HMGB1 levels over 24 h. (A) Serum and (B) urine levels of HMGB1 in the sepsis (no apheresis intervention) group at different time points. Data are presented as the mean ± standard deviation. #P<0.05 vs. 0‑h value. HMGB1, high mobility group box protein 1.

Article Snippet: Serum and urine HMGB1 levels were measured using a Human HMGB1 ELISA kit (E-EL-H1554c, Elabscience Biotechnology Co., Ltd., Wuhan, China) according to the manufacturer's protocol.

Techniques: Standard Deviation

Journal: Experimental and therapeutic medicine

Article Title: Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis.

doi: 10.3892/etm.2017.4854

Figure Lengend Snippet: Figure 3. Association of serum HMGB1 level with urine HMGB1 level and APACHE II score. Correlations were identified between (A) urine and serum HMGB1 levels, and (B) APACHE II score and serum HMGB1 level in the sepsis (no apheresis intervention) group. HMGB1, high mobility group box protein 1; APACHE II, Acute Physiology and Chronic Health Evaluation II.

Article Snippet: Serum and urine HMGB1 levels were measured using a Human HMGB1 ELISA kit (E-EL-H1554c, Elabscience Biotechnology Co., Ltd., Wuhan, China) according to the manufacturer's protocol.

Techniques:

Journal: Experimental and therapeutic medicine

Article Title: Blood purification treatment initiated at the time of sepsis diagnosis effectively attenuates serum HMGB1 upregulation and improves patient prognosis.

doi: 10.3892/etm.2017.4854

Figure Lengend Snippet: Figure 4. Changes in serum and urine HMGB1 levels in the different patient groups over 24 h. (A) Serum and (B) urine levels of HMGB1 were measured by ELISA at different time points after the initiation of treatments. Data are presented as the mean ± standard deviation. #P<0.05 vs. 0‑h value; *P<0.05 vs. sepsis group; ^P<0.05 vs. 12‑h value. HMGB1, high mobility group box protein 1; CRRT, continuous renal replacement treatment; HP, hemoperfusion.

Article Snippet: Serum and urine HMGB1 levels were measured using a Human HMGB1 ELISA kit (E-EL-H1554c, Elabscience Biotechnology Co., Ltd., Wuhan, China) according to the manufacturer's protocol.

Techniques: Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Molecular medicine reports

Article Title: MicroRNA‑22 alleviates inflammation in ischemic stroke via p38 MAPK pathways.

doi: 10.3892/mmr.2019.10269

Figure Lengend Snippet: Figure 2. Downregulation of miRNA‑22 increases inflammatory factor expression in the in vitro stroke model. (A) miRNA‑22 expression and levels of (B) TNF‑α, IL‑1β, IL‑6, IL‑18, MIP‑2 and PGE2. ##P<0.01 vs. control group. miRNA‑22, microRNA‑22; Anti‑22, downregulation of miRNA‑22 group; TNF, tumor necrosis factor; IL, interleukin; MIP, macrophage inflammatory protein; PGE2, prostaglandin E2.

Article Snippet: Serum was incubated with tumor necrosis factor (TnF)-α, interleukin (il)-1β, il-6, il-18, MiP-2, PGe2 (all elabscience Biotechnology co. ltd., Wuhan, china), caspase-3 (c1115, Beyotime institute of Biotechnology, nanjing china) and caspase-9 (c1158, Beyotime institute of Biotechnology) commercial eliSa kits.

Techniques: Expressing, In Vitro, Control

Journal: Molecular medicine reports

Article Title: MicroRNA‑22 alleviates inflammation in ischemic stroke via p38 MAPK pathways.

doi: 10.3892/mmr.2019.10269

Figure Lengend Snippet: Figure 3. Overexpression of miRNA‑22 reduces inflammatory factor expression in the in vitro stroke model. (A) miRNA‑22 expression was successfully increased by mimics. (B) Expression of TNF‑α, IL‑1β, IL‑6, IL‑18, MIP‑2 and PGE2 was determined by ELISA. ##P<0.01 vs. control group. Control, miRNA‑22, overexpression of microRNA‑22 group; TNF, tumor necrosis factor; IL, interleukin; MIP, macrophage inflammatory protein; PGE2, prostaglandin E2.

Article Snippet: Serum was incubated with tumor necrosis factor (TnF)-α, interleukin (il)-1β, il-6, il-18, MiP-2, PGe2 (all elabscience Biotechnology co. ltd., Wuhan, china), caspase-3 (c1115, Beyotime institute of Biotechnology, nanjing china) and caspase-9 (c1158, Beyotime institute of Biotechnology) commercial eliSa kits.

Techniques: Over Expression, Expressing, In Vitro, Enzyme-linked Immunosorbent Assay, Control

Journal: Molecular medicine reports

Article Title: MicroRNA‑22 alleviates inflammation in ischemic stroke via p38 MAPK pathways.

doi: 10.3892/mmr.2019.10269

Figure Lengend Snippet: Figure 7. p38 inhibitor reduces the proinflammatory effects of Anti‑22 in the in vitro stroke model. TNF‑α, IL‑1β, IL‑6, IL‑18, MIP‑2 and PGE2 expression was determined by ELISA. ##P<0.01 compared with control group, **P<0.01 compared with downregulation of microRNA‑22 group. Anti‑22, downregulation of microRNA‑22 group; Anti‑22+p38 i, downregulation of miRNA‑22 and p38 inhibitor group; TNF, tumor necrosis factor; IL, interleukin; MIP, macrophage inflammatory protein; PGE2, prostaglandin E2.

Article Snippet: Serum was incubated with tumor necrosis factor (TnF)-α, interleukin (il)-1β, il-6, il-18, MiP-2, PGe2 (all elabscience Biotechnology co. ltd., Wuhan, china), caspase-3 (c1115, Beyotime institute of Biotechnology, nanjing china) and caspase-9 (c1158, Beyotime institute of Biotechnology) commercial eliSa kits.

Techniques: In Vitro, Expressing, Enzyme-linked Immunosorbent Assay, Control